The World Health Organization estimates that 1.28 billion people worldwide have high blood pressure, two-thirds of whom live in low- and middle-income countries. The chronic condition, characterised by abnormally high blood pressure in the blood vessels, is responsible for 10.8 million deaths each year. But a new treatment could have a major impact on reducing the risk of cardiovascular disease linked to high blood pressure. It is a combination tablet of three antihypertensive drugs, known as GMRx2, which has shown superior results to a high-quality standard treatment. The results of the trial, led by the George Institute for Global Health in Australia, were presented today at the European Society of Cardiology Congress 2024 and published in the Journal of the American Medical Association (JAMA).
A 10% reduction in risk
The GMRx2 treatment plan involved a daily pill containing telmisartan, amlodipine, and indapamide at a quarter, half, or standard dose. After 6 months of treatment, home systolic blood pressure was 31 mmHg lower in the GMRx2 group, compared with 26 mmHg with standard care. The difference of 5.8 mmHg is statistically significant. Indeed, existing data show that for every 5 mmHg reduction in (…)
- Top Santé
It turns out there is a best time to take collagen supplements
Intermittent Fasting Reverses Fatty Liver Disease in 3 Months
Here’s the Best Time of Day to Eat Protein, According to Researcher
“I thought I was suffering from simple acid reflux, but I actually had aggressive stomach cancer”
Having trouble falling asleep? Here’s the number 1 mistake insomniacs make
